(Q40340899)

English

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

scientific article published on 13 December 2010

Statements

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study (English)
Michael Andersson
Elisabeth Lidbrink
Karsten Bjerre
Erik Wist
Kristin Enevoldsen
Anders B Jensen
Per Karlsson
Ulla B Tange
Peter G Sørensen
Susanne Møller
Jonas Bergh
Sven T Langkjer
13 December 2010
264-271

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit